Trial | NCT01489852  Report issue

Title

Estrogen Pretreatment Prior to GnRH Antagonist Protocol
Interest of a Steroid Pre-treatment Prior to IVF Protocol With Ovarian Stimulation by Recombinant FSH and With LH Surge Blockage by Daily GnRH Antagonist

  • Phase

    Phase 4

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Intervention/Treatment

    estradiol ...

  • Study Participants

    472
The purpose of this study is to assess whether estrogen pre-treatment can allow retrieval of 2 additional oocytes in GnRH antagonist protocol.
Study Started
Dec 31
2006
Primary Completion
Jul 31
2010
Study Completion
May 31
2011
Last Update
Dec 12
2011
Estimate

Drug 17beta-estradiol

Pretreatment with 17beta-estradiol (Provames®, Aventis, Paris, France) was administered daily (2 mg twice a day) during the cycle preceding the IVF/ICSI cycle, starting 7 days before the predicted onset of menses and administered up until to the following Thursday after the occurrence of menses.

Estrogen pre-treatment Active Comparator

Control No Intervention

The control group did not receive any pre-treatment.

Criteria 

Inclusion Criteria:

regular normo-ovulatory cycles (28 to 35 days)
age < 38 years,
body mass index (BMI) between 18 and 30
first or second IVF/ICSI attempt

Exclusion Criteria:

high basal levels of serum FSH or E2,
less than 5 follicles at the antral follicular count performed on day 3 of a spontaneous cycle,
history of high (>20 oocytes) or low (< 5 oocytes) ovarian response in a previous IVF attempt
No Results Posted